Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth
Executive Summary
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.
You may also be interested in...
Bausch + Lomb Patiently 'Semi-Private' While Bausch Health Plots Path To Spin-Out Completion
B+L using period of Bausch Health’s near-full ownership to plan for future. "When the spin comes, then we can spend a lot more time with our investors. But right now, I just have to take the elevator down two floors and I can see the 90% shareholder,” says CEO Brent Saunders.
HBW Executive Decisions: CDER Compliance Director, CRN Communications VP, Bayer, B+L CEOs
CDER Compliance director Furman no longer acting; former FDA communications director joins CRN; USANA marketing chief On Utah Business’s List; FTC launches Technology Office; and Bayer and Bausch + Lomb appoint CEOs.
Consumer Products Drive B+L Sales As Spinout Expenses, Increasing Costs Drag Results
Consumer health products account for majority of vision care sales during Q4 and all 2022, with launch of Lumify eye drops in Canada a key driver. “While consumers have faced pressure from higher inflation and potential economic uncertainty, we have not seen broad, fundamental changes in the segment,” says CFO Sam Eldessouky.